Variability in the response to cyclooxygenase inhibitors: Toward the individualization of nonsteroidal anti-inflammatory drug therapy

Journal of Investigative Medicine

Volumn 57, Issue 6, 2009, Pages 709-716

  Grosser, Tilo ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

COX 2; NSAIDs; Personalized medicine

Indexed keywords

ARACHIDONIC ACID; CELECOXIB; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; IBUPROFEN; LUMIRACOXIB; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PARECOXIB; PROSTACYCLIN; PROSTAGLANDIN D2; PROSTAGLANDIN E2; PROSTAGLANDIN F2 ALPHA; PROSTAGLANDIN SYNTHASE INHIBITOR; ROFECOXIB; THROMBOXANE; VALDECOXIB;

ACETYLATION; ANALGESIA; ARTHRITIS; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CIRCADIAN RHYTHM; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; ENVIRONMENTAL FACTOR; ENZYME SYNTHESIS; FEVER; GASTROINTESTINAL SYMPTOM; GASTROINTESTINAL TOXICITY; GENETIC VARIABILITY; HEART INFARCTION; HEART PROTECTION; HUMAN; HYPERTENSION; INFLAMMATION; PLASMA PROTEIN BINDING; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; RISK BENEFIT ANALYSIS; RISK REDUCTION; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; SUDDEN DEATH; THROMBOCYTE ACTIVATION; THROMBOSIS; TREATMENT RESPONSE; ULCER;

CARDIOVASCULAR DISEASES; CYCLOOXYGENASE 2 INHIBITORS; HUMANS; RISK ASSESSMENT; TREATMENT OUTCOME;

EID: 70349235481     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: 10.2310/JIM.0b013e3181b04d1f     Document Type: Conference Paper

References (62)

1. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116(1):4-15.
2. Day RO, Graham GG, Williams KM, et al. Variability in response to NSAIDs. Fact or fiction? Drugs. 1988;36(6):643-651.
3. Fries S, Grosser T, Price TS, et al. Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2. Gastroenterology. 2006;130(1):55-64.
4. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001;293(5531):876-880.
5. Berns K, Horlings HM, Hennessy BT, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007;12(4):395-402.
6. Schwarz UI, Ritchie MD, Bradford Y, et al. Genetic determinants of response to warfarin during initial anticoagulation. N Engl J Med. 2008;358(10):999-1008.
7. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR study group. N Engl J Med. 2000;343(21):1520-1528, 1522 p following 1528.
8. Ott E, Nussmeier NA, Duke PC, et al. Efficacy and safety of the cyclooxygenase 2 inhibitors parecoxib and valdecoxib in patients undergoing coronary artery bypass surgery. J Thorac Cardiovasc Surg. 2003;125(6):1481-1492.
9. Nussmeier NA, Whelton AA, Brown MT, et al. Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med. 2005;352(11):1081-1091.
10. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet. 2004;364(9435): 665-674. (Pubitemid 39140622)
11. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet. 2006;368(9549):1771-1781.
12. Grosser T, Yusuff S, Cheskis E, et al. Developmental expression of functional cyclooxygenases in zebrafish. Proc Natl Acad Sci U S A. 2002;99(12):8418-8423.
13. Smyth EM, Grosser T, Wang M, et al. Prostanoids in health and disease. J Lipid Res. 2009;50Suppl:S423-S428.
14. Narumiya S, FitzGerald GA. Genetic and pharmacological analysis of prostanoid receptor function. J Clin Invest. 2001;108(1):25-30.
15. Garavito RM, DeWitt DL. The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins. Biochim Biophys Acta. 1999;1441(2-3):278-287.
16. Picot D, Loll PJ, Garavito RM. The x-ray crystal structure of the membrane protein prostaglandin H2 synthase-1. Nature. 1994; 367(6460):243-249.
17. Bresalier RS, Sandler RS, Quan H, et al. Cardiovascular eventsassociated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102.
18. Zimmermann KC, Sarbia M, Schror K, et al. Constitutive cyclooxygenase-2 expression in healthy human and rabbit gastric mucosa. Mol Pharmacol. 1998;54(3):536-540.
19. Mizuno H, Sakamoto C, Matsuda K, et al. Induction of cyclooxygenase-2 in gastric mucosal lesions and its inhibition by the specific antagonist delays healing in mice. Gastroenterology. 1997;112(2):387-397.
20. Shigeta J, Takahashi S, Okabe S. Role of cyclooxygenase-2 in the healing of gastric ulcers in rats. J Pharmacol Exp Ther. 1998;286(3): 1383-1390.
21. Lipsky PE, Brooks P, Crofford LJ, et al. Unresolved issues in the role of cyclooxygenase-2 in normal physiologic processes and disease. Arch Intern Med. 2000;160(7):913-920.
22. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti- inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000;284(10):1247-1255.
23. Singh G, Fort JG, Goldstein JL, et al. Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I study. Am J Med. 2006;119(3):255-266.
24. Witter J. Celebrex Capsules (Celecoxib). NDA 20-998/S-009. Medical Officer Review. Silver Spring, MD: US Department of Health and Human Services Food and Drug Administration; 2000.
25. Fries JF, Murtagh KN, Bennett M, et al. The rise and decline of nonsteroidal antiinflammatory drug-associated gastropathy in rheumatoid arthritis. Arthritis Rheum. 2004;50(8):2433-2440.
26. Arehart E, Stitham J, Asselbergs FW, et al. Acceleration of cardiovascular disease by a dysfunctional prostacyclin receptor mutation: potential implications for cyclooxygenase-2 inhibition. Circ Res. 2008;102(8):986-993.
27. 2. Science. 2002; 296(5567):539-541.
28. Cheng Y, Wang M, Yu Y, et al. Cyclooxygenases, microsomal prostaglandin E synthase-1, and cardiovascular function. J Clin Invest. 2006;116(5):1391-1399.
29. 2 and prostacyclin in the development of atherosclerosis in apoE-deficient mice. J Clin Invest. 2004;114(6):784-794.
30. Egan KM, Lawson JA, Fries S, et al. COX-2-derived prostacyclin confers atheroprotection on female mice. Science. 2004;306(5703): 1954-1957.
31. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1997;388(6643):678-682.
32. Solomon DH, Glynn RJ, Rothman KJ, et al. Subgroup analyses to determine cardiovascular risk associated with nonsteroidal antiinflammatory drugs and coxibs in specific patient groups. Arthritis Rheum. 2008;59(8):1097-1104.
33. Pini B, Grosser T, Lawson JA, et al. Prostaglandin E synthases in zebrafish. Arterioscler Thromb Vasc Biol. 2005;25(2):315-320.
34. Wang M, Zukas AM, Hui Y, et al. Deletion of microsomal prostaglandin E synthase-1 augments prostacyclin and retards atherogenesis. Proc Natl Acad Sci U S A. 2006;103(39):14507-14512.
35. Wang M, Lee E, Song W, et al. Microsomal prostaglandin E synthase-1 deletion suppresses oxidative stress and angiotensin IIYinduced abdominal aortic aneurysm formation. Circulation. 2008;117(10): 1302-1309.
36. Patrono C, Garcia Rodriguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med. 2005;353(22): 2373-2383.
37. Boutaud O, Aronoff DM, Richardson JH, et al. Determinants of the cellular specificity of acetaminophen as an inhibitor of prostaglandin H2 synthases. Proc Natl Acad Sci U S A. 2002;99(10):7130-7135.
38. Verbeeck RK, Blackburn JL, Loewen GR. Clinical pharmacokinetics of non-steroidal anti-inflammatory drugs. Clin Pharmacokinet. 1983;8(4):297-331.
39. Day RO, McLachlan AJ, Graham GG, et al. Pharmacokinetics of nonsteroidal anti-inflammatory drugs in synovial fluid. Clin Pharmacokinet. 1999;36(3):191-210.
40. Patrignani P. Lumiracoxib: a viewpoint by Paola Patrignani. Drugs. 2004;64(19):2247-2248.
41. Scott G, Rordorf C, Reynolds C, et al. Pharmacokinetics of lumiracoxib in plasma and synovial fluid. Clin Pharmacokinet. 2004;43(7):467-478.
42. Hinz B, Renner B, Cheremina O, et al. Lumiracoxib inhibits cyclo-oxygenase 2 completely at the 50 mg dose: is liver toxicity avoidable by adequate dosing? Ann Rheum Dis. 2009;68(2):289-291.
43. Grosser T. The pharmacology of selective inhibition of COX-2. Thromb Haemost. 2006;96(4):393-400.
44. Patrignani P, Panara MR, Greco A, et al. Biochemical and pharmacological characterization of the cyclooxygenase activity of human blood prostaglandin endoperoxide synthases. J Pharmacol Exp Ther. 1994;271(3):1705-1712.
45. FitzGerald GA, Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345(6):433-442.
46. Warner TD, Giuliano F, Vojnovic I, et al. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc Natl Acad Sci U S A. 1999;96(13):7563-7568.
47. Garcia Rodriguez LA, González-Pérez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC. 2005;3:17.
48. Schwartz JI, Dallob AL, Larson PJ, et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 versus COX-1 in healthy subjects. J Clin Pharmacol. 2008;48(6):745-754.
49. Reilly IA, FitzGerald GA. Inhibition of thromboxane formation in vivo and ex vivo: implications for therapy with platelet inhibitory drugs. Blood. 1987;69(1):180-186.
50. Aw TJ, Haas SJ, Liew D, et al. Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med. 2005; 165(5):490-496.
51. Burleigh ME, Babaev VR, Oates JA, et al. Cyclooxygenase-2 promotes early atherosclerotic lesion formation in LDL receptorYdeficient mice. Circulation. 2002;105(15):1816-1823.
52. Egan KM, Wang M, Lucitt MB, et al. Cyclooxygenases, thromboxane, and atherosclerosis: plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation. 2005;111(3):334-342.
53. Capone ML, Sciulli MG, Tacconelli S, et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol. 2005;45(8):1295-1301.
54. Wilcox CM, Allison J, Benzuly K, et al. Consensus development conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol. 2006;4(9):1082-1089.
55. Arboleya LR, de la Figuera E, Soledad Garcia M, et al. Experience of rofecoxib in patients with osteoarthritis previously treated with traditional non-steroidal anti-inflammatory drugs in Spain: results of phase 2 of the VICOXX study. Curr Med Res Opin. 2003;19(4): 288-297.
56. Zhao SZ,Wentworth C, Burke TA, et al. Drug switching patterns among patients with rheumatoid arthritis and osteoarthritis using COX-2 specific inhibitors and non-specific NSAIDs. Pharmacoepidemiol Drug Saf. 2004;13(5):277-287.
57. Markiewicz A, Semenowicz K. Time dependent changes in the pharmacokinetics of aspirin. Int J Clin Pharmacol Biopharm. 1979;17(10):409-411.
58. Labrecque G, Dore F, Belanger PM. Circadian variation of carrageenan-paw edema in the rat. Life Sci. 1981;28(12):1337-1343.
59. Rudic RD, McNamara P, Reilly D, et al. Bioinformatic analysis of circadian gene oscillation in mouse aorta. Circulation. 2005;112(17): 2716-2724.
60. FDA. New Drug Application 20-998. Clinical Pharmacology and Biopharmaceutics Review Celecoxib. Bethesda, MD: Food and Drug Administration; 1998.
61. Tang C, Shou M, Mei Q, et al. Major role of human liver microsomal cytochrome P450 2C9 (CYP2C9) in the oxidative metabolism of celecoxib, a novel cyclooxygenase-II inhibitor. J Pharmacol Exp Ther. 2000;293(2):453-459.
62. Wang M, Song WL, Cheng Y, et al. Microsomal prostaglandin E synthase-1 inhibition in cardiovascular inflammatory disease. J Intern Med. 2008;263(5):500-505.